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Introduction
Germline truncating mutations in the tumour-suppressor gene CYLD have been associated with three disfiguring hair follicle tumour syndromes: (i) familial cylindromatosis, (ii) Brooke-Spiegler syndrome and (iii) multiple familial trichoepitheliomas (Bowen et al., 2005) . CYLD mutant patients develop three distinct types of cutaneous tumours, namely cylindromas, spiradenomas and trichoepitheliomas. The presence of painful spiradenomas and truncal and genital tumours can have a significant impact on quality of life, as can the surgery used to remove lesions as this may culminate in entire scalp removal. As such, development of nonsurgical approaches to control tumour burden are required (Rajan et al., 2009) . Novel therapeutic approaches using inhibitors of the nuclear factor-kB (NFkB) pathway such as aspirin were proposed when CYLD was found to encode a ubiquitin hydrolase that negatively regulated this pathway (Brummelkamp et al., 2003; Kovalenko et al., 2003; Trompouki et al., 2003) . However, initial clinical studies with topical salicylic acid showed a significant response in only a small proportion of treated tumours (Oosterkamp et al., 2006) . Therefore, a more detailed understanding of the molecular dysregulation caused by loss of functional CYLD is warranted, and this may inform the development of novel therapeutic approaches.
CYLD encodes a ubiquitin hydrolase that cleaves lysine-63 (K63)-linked ubiquitin chains (Brummelkamp et al., 2003; Kovalenko et al., 2003; Trompouki et al., 2003) , the specificity of which depends on the presence of a B-box domain within the CYLD protein (Komander et al., 2008) . In patients with germline CYLD mutations, the majority (94%) of mutations result in premature termination codons and predict translated truncated proteins that have reduced catalytic activity (Saggar et al., 2008) , which in turn is thought to perturb the regulation of the NFkB pathway. CYLD substrates, including TRAF2, TRAF6 and NEMO, which regulate canonical NFkB signalling, are regulated by K63 ubiquitin tagging, and lack of functional CYLD results in constitutively active NFkB signalling (Brummelkamp et al., 2003; Kovalenko et al., 2003; Trompouki et al., 2003) . CYLD interacts with and negatively regulates TAK1, reducing TAK1-mediated stimulation of IKK and hence activation of NFkB (Reiley et al., 2007) . TAK1 also phosphorylates and activates MKK6 and MKK7, leading to the activation of the p38 and JNK kinase pathways, which may also contribute to disease pathogenesis (Reiley et al., 2004; Liu et al., 2006) . CYLD negatively regulates BCL3, preventing nuclear entry where it forms a dimer with p50/p52, resulting in the transcription of genes involved in proliferation, including cyclin-D1 . CYLD was also shown to negatively regulate Wnt signalling, recognised to have a role in tumorigenesis, by deubiquitinating Dishevelled (Tauriello et al., 2010) . Additional roles for CYLD have been suggested in the regulation of immunity, microtubule assembly, calcium ion channel regulation and facilitating entry into mitosis. (Reiley et al., 2006; Stokes et al., 2006; Stegmeier et al., 2007; Gao et al., 2008) . How perturbation of these pathways by loss of functional CYLD contributes to tumour formation is not yet clear.
Apart from cylindromas, other cancers that lack functioning CYLD or have reduced expression of CYLD include hepatocellular and colonic carcinoma (Hellerbrand et al., 2007) , multiple myeloma (Annunziata et al., 2007; Jenner et al., 2007; Keats et al., 2007; Demchenko et al., 2010) , lung cancer (Zhong et al., 2007) , prostate cancer (Kikuno et al., 2008) and malignant melanoma (Massoumi et al., 2009) . In multiple myeloma, loss of heterozygosity (LOH) at 16q, the genomic location of the CYLD gene, is an indicator of poor prognosis and is associated with reduced overall survival (Jenner et al., 2007) . Both deletions involving the locus of CYLD resulting in reduced copy number as well as biallelic events, comprising a 16q deletion with mutations within the coding exons of CYLD in the remaining allele, have been shown (Demchenko et al., 2010) . Overexpression of NFkB target genes has been shown in myeloma consistent with the proposed role of CYLD (Jenner et al., 2007) .
CYLD-deficient mouse models with complete loss of CYLD expression do not develop spontaneous tumours, but show an increased susceptibility to cancer. This includes an increased susceptibility to chemical carcinogen-induced cutaneous tumours (Massoumi, 2006) as well as colorectal tumours following dextran sulphateinduced colitis . Mice expressing truncated CYLD mutations that mimic human mutations, by contrast, are not viable beyond a few hours after birth (Trompouki et al., 2009) . This difference in the two phenotypes is intriguing and suggests that further work is required to understand genotypephenotype correlations.
CYLD has been shown to interact with tropomyosin kinase-A (TRKA) and has a role in receptor internalisation and signal transduction (Geetha et al., 2005) . TRK receptors were first recognised to have a tumorigenic role when an oncogenic TRK fusion protein was found in a proportion of colonic carcinomas (Martin-Zanca et al., 1986) and subsequently thyroid carcinomas (Butti et al., 1995) . Dysregulation of TRK signalling has also been shown in a number of epithelial tumours (Weeraratna et al., 2000; Ricci et al., 2001; Lagadec et al., 2009) .
Here, we have performed a detailed molecular analysis of tumours from patients with CYLD mutations. This showed upregulation of TRK signalling in CYLD-defective tumours. We went on to develop a three-dimensional (3D) cell culture model from primary tumour cells to show the potential of therapeutically targeting TRK for the treatment of these tumours.
Results
Cylindroma and spiradenomas tumours are similar and are genomically stable Fresh frozen tumours from patients with germline CYLD mutations were microdissected to isolate tumour cells and perilesional control cells. Genomic analysis of cylindroma and spiradenoma tissue was performed on 12 tumours and seven perilesional skin samples using a 32K bacterial artificial chromosome (BAC) tiling path array (Natrajan et al., 2009) . This BAC array platform has been shown to be as robust as, and to have a comparable resolution with, high-density oligonucleotide arrays (Coe et al., 2007; Tan et al., 2007; Gunnarsson et al., 2008) . Comparative genomic hybridisation was performed using DNA extracted from peripheral blood leukocytes from the same patient as the reference. No obvious regional genomic amplification or deletion was noted in the 12 tumour samples ( Figure 1a ). Moreover, no difference was seen between cylindromas (n ¼ 7) and spiradenomas (n ¼ 5).
Given the apparent absence of genomic copy-number variation observed using BAC arrays, we went on to perform high-resolution single-nucleotide polymorphism (SNP) typing using a 550K SNP array platform (Illumina, San Diego, CA, USA) on four cylindroma tumours and one control sample. This showed a copynumber silent LOH for the entire arm of chromosome 16q in all four tumours but no other significant changes ( Figure 1b ).
The LOH status at the site of the mutation was assessed in a further 27 tumours used in this study, which was possible as the genotype of each patient was known. LOH was assessed using genomic DNA from microdissected tumours by using restriction enzymes that specifically were unable to cut only the mutated allele in each tumour. PCR amplification was performed using primers that flanked exon-18, and the PCR product was subject to restriction enzyme digestion using enzymes chosen for pedigree-specific mutations: HpyCH4V (c.2460delc) and SmlI (c.2469 þ 1G4A). This showed LOH at the site of the mutation in 75% of the 27 tumours, suggesting the mechanism resulting in LOH to be similar in the majority of tumours.
TRK signalling is dysregulated in cylindroma and spiradenoma tissue Gene expression profiling was performed on total RNA extracted from 42 microdissected samples, consisting of 19 cylindromas, 9 spiradenomas, 4 trichoepitheliomas and 10 perilesional controls. A bead array platform (Illumina) that is capable of assaying the expression of 24 526 transcripts for each sample was used (April et al., 2009 ). The average signal values from replicate beads Targeting TRK in CYLD defective tumours N Rajan et al were summarised, log-transformed and normalised using quantile normalisation across all samples (Workman et al., 2002; Dunning et al., 2008) . Unsupervised clustering analysis of the individual transcriptomes (24 526 probes) by Euclidean distance showed close clustering of the majority of cylindroma and spiradenoma tissue, and distinct clustering of the perilesional skin and trichoepithelioma tissue ( Figure 2 ). This was corroborated with clustering by an independent technique that used multiple bootstrapping to determine the robustness of the clusters. Clustering of transcriptomes using individual probes (24 526) was used and dissimilarity was measured using the correlation method using a statistical package (pvclust) (Suzuki and Shimodaira, 2006) . Clusters were maintained; however, because of the small numbers of tumours used, statistical significance was seen between tumours and controls (Po0.01), but not between tumour subsets (Supplementary Figure 3 ). The unsupervised clustering analysis was further corroborated by a supervised clustering analysis, allowing class comparison between cylindroma and spiradenoma tumours. Nineteen cylindromas and nine spiradenomas were subject to significance of microarrays analysis, which showed no significant difference between the tumour types when standard criteria were applied (Supplementary Figure 4) . (Differentially expressed genes between the two groups had to pass a significance threshold of Po0.01 and 100 permutations of the data were analysed.) Quantitation of differential gene expression was determined using the custom algorithm of the bead array manufacturer (Illumina custom method; Illumina Inc, 2009 ). The statistical significance of differential gene expression between tumours and samples was calculated as a differential score. This calculation incorporated the difference in signal values between the two groups compared, corrected for appropriate negative control bead values, and was corrected for multiple hypothesis testing using a Bonferroni post test. We used stringent thresholds for filtering genes, with only transcripts that Figure 1 Cylindroma and spiradenomas tumours are genomically similar and show stability. (a) Genomic DNA was extracted from seven cylindroma and five spiradenoma microdissected tumours, and competitively hybridised against patient-matched peripheral lymphocyte DNA on a 32K BAC tiling path array. No significant copy-number change was seen between tumours and perilesional skin; an indicative result is shown. (b) To examine for genomic changes at higher resolution, SNP typing was performed using a 550K SNP array in a further 4 cylindromas. LOH was seen across the entire arm of chromosome 16q in all 4 samples, indicated by the red arrow. In panel a, circular binary segmentation (cbs)-smoothed Log 2 ratios are plotted on the Y axis against each BAC clone according to genomic location on the x-axis. BACs categorised as showing genomic gains or amplification are plotted in green, and those categorised as genomic losses in red. BAC, bacterial artificial chromosome; SNP, single-nucleotide polymorphism.
Targeting TRK in CYLD defective tumours N Rajan et al were differentially expressed with a P-value of o0.01 included for subsequent analysis (n ¼ 4492). Given the genomic and transcriptomic similarity seen in cylindromas and spiradenomas, these were pooled and analysed against pooled controls to provide enhanced statistical robustness.
Transcripts of proteins that were previously noted to be overexpressed in cylindromas were also present and supported the enrichment of cylindroma tissue following microdissection. These included numerous laminins (Table 1) (Tunggal et al., 2002) , collagen-4 and 7 (Timpl et al., 1984; Bruckner-Tuderman et al., 1991) , and cytokeratins (Tellechea et al., 1995; Meybehm and Fischer, 1997) , which were preferentially expressed in the tumours compared with perilesional epidermis.
Upregulation of NFkB target genes (http://people. bu.edu/gilmore/nf-kb/target/index.html) was present as expected and served as an internal positive control. All tumours were compared to all controls, and the NFkB target genes that were differentially expressed with a P-value of o0.01 have been tabulated in Table 1. To detect low-level changes in gene expression between all tumours and all control tissue, gene set enrichment analysis was performed on data filtered at a threshold of Po0.05 (Subramanian et al., 2005) . This highlighted multiple gene sets that were involved in apoptosis, and genes that were common to these sets were found to be members of or target genes of the NFkB and JNK signalling pathways ( Figure 3 and Supplementary Figure 1 ).
Fold change (FC) analysis (Table 2) showed overexpression of several members of the TRK signalling pathway, namely, TRKC (fold change ¼ 4.75 Â ), neurotrophin-3 (fold change ¼ 3.00 Â ) and neurotrophin-4/5 (fold change ¼ 3.15 Â ), in the tumour group when compared with perilesional skin. This finding was corroborated by connectivity mapping analysis (Lamb, 2006) using Ingenuity Pathways Analysis (Ingenuity Systems, Redwood City, CA, USA; www.ingenuity. com). This highlighted the concerted overexpression of multiple members of the neurotrophin/TRK signalling pathway in tumour tissue compared with control tissue (P ¼ 4.02 Â 10 À3 ). In addition to the transcripts related to the TRK signalling pathway detected by the fold change analysis above, TRKB, brain-derived neurotrophic factor (BDNF) and PIK3R1, which encodes a regulatory subunit of phosphatidylinositol-3-kinase, a downstream mediator of TRK signalling, were elevated in expression ( Figure 4 ). Moreover, TRKA, a previously described CYLD-interacting protein (Geetha et al., 2005) , was found to be downregulated, whereas the cognate ligand nerve growth factor (NGF) was upregulated. No obvious changes in copy number were found at the chromosomal location of the different TRK receptors and their respective cognate ligands, suggest- Figure 2 Cylindromas and spiradenomas share similar transcriptomes, and cluster distinctly from trichoepitheliomas and perilesional control skin. Total RNA was extracted from 32 microdissected tumours and 10 perilesional controls, and the gene expression levels of 24 526 transcripts for each sample were assayed. Unsupervised clustering of the 42 transcriptomes was performed, and cylindromas and spiradenomas clustered together, with trichoepitheliomas and perilesional skin clustering separately. No clustering by gender, genotype or tumour location was seen.
Targeting TRK in CYLD defective tumours N Rajan et al ing that genomic amplification or deletion was not directly responsible for these changes in transcript level.
TRKB and TRKC proteins are overexpressed in human cylindromas and spiradenomas We investigated whether the overexpression of TRKB and TRKC observed at the mRNA level was reflected in elevated protein expression in CYLD tumours. We constructed a tumour tissue microarray (TMA) of CYLD-deficient tumours cylindromas, spiradenomas, trichoepitheliomas and perilesional skin, and analysed it by immunohistochemistry. Expression of TRKB and TRKC was elevated in cylindroma, spiradenoma and to a lesser extent in trichoepithelioma tissue compared with perilesional skin (Figure 5a ). Strong membranous staining was apparent in cylindroma cells, whereas diffuse cytoplasmic staining was noted in overlying keratinocytes. TRKC expression was mainly noted over the basophilic peripheral cells in cylindroma islands, whereas TRKB overexpression was non-discriminatory within tumour islands ( Figure 5a ). Quantification of membranous TRK expression was performed on each core of the TMA. A scoring scale, which assessed the intensity of membranous TRK staining and the pro-portion of tumour cells stained, was used (Figures 5b and c), and the difference in expression between tumours and perilesional keratinocytes was found to be statistically significant (Po0.05) (Tables 3 and 4 ). Furthermore, cylindroma cells were strongly positive with antibodies against phosphorylated ERK (p44/42), a marker of active TRK signalling, mainly at the periphery of each tumour island. The antiapoptotic protein BCL2, a downstream target of TRK signalling, was also overexpressed in cylindroma tissue, showing strong perinuclear staining (Figure 5a ).
TRKB and TRKC silencing reduces cell viability and colony formation
To assess the functional significance of TRKB and TRKC in cylindromas, primary cell cultures were established from fresh tumour samples obtained from patients who contributed samples used for the molecular profiling and functional studies ( Figure 6a ). Cylindroma tissue was microdissected from normal perilesional tissue under a stereomicroscope, subject to enzymatic digestion to obtain a single-cell suspension and cultured under standard conditions (5% CO 2 , 21% O 2 ). These primary cell cultures were used within 4 weeks of surgery to protect against culture-induced genomic alterations.
To validate these cultures, CYLD expression was characterised and these cells did not express full-length CYLD, which was observed in perilesional fibroblast culture ( Figure 6b ). Cylindroma cells in culture expressed cytokeratin-6, 14, 17 and smooth-muscle actin, markers that were shown to be present in cylindroma tumours in vivo, confirming the purity of the cultures (Figures 6c and d) . These primary cells were transduced with lentiviruses expressing short-hairpin RNAs targeting TRKB and TRKC. The short-hairpin RNA vectors carried a green fluorescent protein (GFP) reporter allowing monitoring of delivery and a puromycin gene allowing selection-cells were grown in media containing puromycin for 48 h after transfection, resulting in cultures that were approximately 100% GFP-positive when analysed. TRKB and TRKC knockdown was assayed using immunoblotting (Figures 6e and f) and after 10-14 days in culture, cells were fixed, stained and colonies were counted. Primary cells with TRKB and TRKC knockdown showed a modest reduction (20-40%; Po0.05) in colony formation (Figure 6g ).
3D primary cell cultures of cylindroma cells are sensitive to TRK inhibitors
The primary cell cultures described above expressed only low levels of TRK, an observation made in previous studies (Lagadec et al., 2009) . To establish a more biologically relevant cylindroma culture model, we seeded primary cells on 3D polystyrene tissue culture scaffolds to allow enhanced cell-cell contact (Figure 7a ). This caused increased the expression of TRKB and TRKC when compared with matched cells grown in standard two-dimensional (2D) culture (Figures 7b and c). To determine whether TRK signalling was active, we examined the level of phosphorylated ERK and BCL2 after stimulating the cultured cells with the cognate Genes that are upregulated in tumour tissue that have been previously described to be overexpressed in cylindroma tumours (Po0.01) KRT18
3.71 Keratin-8 pseudogene-9; similar to keratin-8 KRT7
2
1.94 Collagen, type-VII, a-1 COL4A1
1.5 Collagen, type-IV, a-1 COL4A2
1.73 Collagen, type-IV, a-2
Abbreviation: NFkB, nuclear factor-kB. Transcripts that were differentially expressed between tumours and perilesional controls were filtered with the criteria of a 4 Â fold change and P-value of o0.01. Transcripts that fulfilled these criteria were compared against known NFkB target genes and tabulated. The purity of tumour microdissection was supported by overexpression of transcripts in cylindroma tissue described previously in the literature.
Targeting TRK in CYLD defective tumours N Rajan et al ligands of the TRK receptors (NGF, BDNF and NT3). Stimulation indeed resulted in increased phosphorylated ERK above basal levels ( Figure 7d ). The antiapoptotic factor BCL2 has been shown to be upregulated in response to NT3 in oligodendrocyte progenitor cells (Saini et al., 2004) . This was recapitulated in our model, where BCL2 expression was increased following stimulation with TRK receptor ligands (Figure 7e ). To determine whether these cultures were dependent on TRK signalling for survival, they were treated with small-molecule TRK kinase inhibitors. As control they were also exposed to salicylic acid, which has been shown previously to effect survival in CYLD-deficient cells (Brummelkamp et al., 2003) . Cells were only modestly sensitive to salicylic acid (surviving fraction (SF 50 ) 1.5 mM), but were much more so to the pan-TRK inhibitors lestaurtinib (CEP-701) (SF 50 , 4.57 mM), AG879 (SF 50 , 4.21 mM) and K252a (SF 50 , 366 nM) ( Figure 8 ). It seems possible that loss of CYLD catalytic activity accounts for the TRK dependency. To address this, we introduced a cDNA construct expressing CYLD into primary tumour cells, with the aim of assessing whether CYLD expression could rescue the phenotypes observed. However, as is often the case when genes are artificially expressed from cDNA constructs, reintroduction of CYLD cDNA resulted in reduced cell viability, precluding further mechanistic studies (Supplementary Figure 5 ).
Membrane-localised TRKC is overexpressed in sporadic BCCs
Cutaneous appendageal tumours seen in CYLD mutation carriers share similarities in cytokeratin profiles with sporadic basal cell carcinoma (BCC), which in humans are thought to be also derived from the hair follicle (Donovan, 2009 ). Dysregulation of several mutual oncogenic pathways are seen in cylindromas and BCCs. Wnt signalling is thought to have an oncogenic role in both, with expression of nuclear b-catenin shown in both cylindromas (Tauriello et al., 2010) and human BCCs (Kriegl et al., 2009) . Also, the Sonic hedgehog pathway, recognised to depend on such canonical Wnt signalling for cutaneous tumour formation (Hoseong Yang et al., 2008) , is an important final common pathway in both tumours. Figure 3 NFkB target genes are overexpressed in CYLD mutant tumours. The expression levels of 24 526 genes from 32 microdissected tumours were pooled and compared against 10 pooled perilesional controls and subject to gene set expression analysis. Sets of genes recognised to modulate apoptosis were found to be overexpressed in the tumour tissue (see also Supplementary Figure 1) . A heat map of the members of one set (HSA04210_APOPTOSIS) is shown here, with overexpressed genes shown in red and underexpressed genes in blue. The overexpressed genes included several NFkB target genes. NFkB, nuclear factor-kB.
Targeting TRK in CYLD defective tumours N Rajan et al In a murine model that overexpresses GLI1 (Nilsson et al., 2000) , tumours that had histological appearances that resembled both human BCCs and cylindroma were seen. Diffuse light expression of TRK receptors has previously been noted in a small series of BCCs using a pan-TRK antibody (Chen-Tsai et al., 2004) . Therefore, we went on to investigate if the membranous TRKB and TRKC overexpression we observed in CYLD mutant tumours was a feature that extended to sporadic skin cancers (Table 5 ). We examined the expression of TRK receptors in a human skin cancer TMA that included samples of squamous cell carcinoma (SCC; n ¼ 19), malignant melanoma (MM; n ¼ 5) and BCC (n ¼ 23), using TRKA-, TRKB-and TRKC-specific antibodies. Interestingly, membranous TRKC was overexpressed in 70% of the BCC (Figure 9 ) and 5% of SCC tumours but not in the melanoma samples. In some samples, TRKC staining was strongest at the invasive front where the tumour cells apposed stroma ( Supplementary Figure 2) . No membranous TRKA staining was seen; however, there was some perinuclear staining, a feature associated with activated TRKA signalling , which was seen in 39% of cases of BCC and 16% of cases of SCC. TRKB staining was seen in the cytoplasm in 13% of BCC cases only, where it was seen in a few cells, but not at the cell membrane.
Discussion
CYLD mutation carriers face repeated, disfiguring surgery to control tumour burden, and in a study of two large pedigrees, up to one in four affected patients underwent total scalp removal (Rajan et al., 2009) . Painful eccrine spiradenomas, development of conductive deafness caused by occlusive tumours in the ear canal and the risk of malignant transformation (Gerretsen et al., 1993) justify the development of nonsurgical alternatives for this patient group. Here, we performed an unbiased approach using genomic and transcriptomic analysis of CYLD-defective tumours. We showed that cylindroma and spiradenoma tumours were genomically similar and stable, with LOH at 16q found in the majority of the tumours in this study. The genomic stability seen across 16 tumours could suggest homogeneity in the mechanisms of pathogenesis and potentially in the response to therapeutic agents. Moreover, it seems possible that genomically stable tumours may be less liable to the acquisition of resistance mechanisms that arise through genomic diversity. We detected the upregulation of transcripts of TRKB and TRKC, and their cognate ligands NT3/NT4 and BDNF in cylindroma and spiradenoma samples. This was of particular interest as CYLD, a de-ubiquitinase with K63-linked ubiquitin specificity, has previously been shown to de-ubiquitinate TRKA and inhibit its internalisation from the cell membrane and subsequent downstream signalling through the phosphatidylinositol-3-kinase pathway (Geetha et al., 2005) . Furthermore, recent studies have shown that BDNF is an NFkB target gene that may afford a neuroprotective role in astrocytes, supporting the finding that this TRK ligand is overexpressed by the cylindroma cells resulting in an autocrine loop (Saha et al., 2006) . Validation of protein Transcripts that were differentially expressed between tumours and perilesional controls were filtered with the criteria of a 4 Â fold change and P-value of less than 0.01. Overexpressed transcripts are shown in red and underexpressed transcripts are shown in green.
Targeting TRK in CYLD defective tumours N Rajan et al expression using TRK-specific antibodies showed strong membranous expression of TRKB and TRKC in cylindromas and spiradenomas, when compared with perilesional epidermis and hair follicles. Finally, downstream targets of TRK signalling such as phosphorylated ERK and BCL2 were overexpressed in the tumours. TRK receptors have received considerable attention as mediators of neuronal growth, survival and maintenance (Huang and Reichardt, 2001) , and have been shown to be expressed in hair follicles (Adly et al., 2005; Blasing et al., 2005) . Their role in cancer was initially shown by uncommon oncogenic fusions involving C-terminal sequences of the NTRK1/NGF receptor gene with 5-terminal sequences of various activating genes such as TPM3, TPR and TFG in colon and papillary thyroid carcinoma (Martin-Zanca et al., 1986; Butti et al., 1995) . Exploitation of the constitutively active prosurvival signalling that is usually restricted to neurons was thought to confer an advantage for the cancer cells. Recent advances in the understanding of complex signalling pathways involved in cancer (Luo et al., 2009 ) has suggested that some neural-derived cancer cells, such as neuroblastoma, may become dependent on TRK signalling for survival, independent of mutations in TRK (Matsumoto et al., 1995; Scala et al., 1996) . Subsequent demonstration of TRK expression associated with a survival advantage in epithelial tumours, including breast (Lagadec et al., 2009) , prostate (Weeraratna et al., 2000) and lung (Ricci et al., 2001) , extended the role of TRK signalling to nonneural-derived tumours. At a genomic level, we established that neither TRKB and TRKC amplification, nor that of BDNF and NT3/4, was shown to account for the overexpression seen in cylindroma tumours, suggesting that CYLD dysfunction perturbs normal TRK homeostasis.
The differential expression of TRKA, TRKB and TRKC in these tumours is intriguing. Whereas TRKA is regulated by CYLD, the interaction of CYLD with TRKB and TRKC remains to be clarified. The low perinuclear expression of TRKA, but conversely the high membranous expression of TRKB and TRKC, suggests that not all TRKs are regulated by CYLD in the same manner. This has been shown to be true with other forms of ubiquitin modification, including monoubiquitination (Are´valo et al., 2006) or Lys48 polyubiquitination (Geetha et al., 2005) . Are´valo et al. showed that an E3 ubiquitin ligase, Nedd4-2, associated with the TRKA receptor and was phosphorylated upon NGF binding, whereas Nedd4-2 did not bind to or ubiquitinate related TRKB receptors, because of the lack of a consensus PPXY motif. These results indicate that TRK receptors are differentially regulated by ubiquitination to modulate the survival of neurons (Are´valo et al., 2006) . Interestingly, Geetha et al. (2008) have shown that the scaffold protein p62, which facilitates the interaction between CYLD and TRKA, is able to bind to specific lysine residues on TRKB (Lys 811) and TRKC (Lys 602 and 815), and mutation of these sites disrupted downstream signalling. This suggests the possibility that CYLD could interact with TRKB and TRKC, but the precise mechanism of TRK specific homeostasis remains to be clarified.
We established that TRK signalling was effective in cylindroma primary cell culture using recombinant human BDNF and NT3 for TRKB and TRKC, respectively, and showed increased expression of phosphorylated ERK and BCL2. To delineate the advantage conferred by TRKB and TRKC overexpression, we used a lentivirus-mediated knockdown system. This showed reduced colony formation in TRKB-and TRKCdeficient cells, supporting the pathogenic role of these receptors.
We attempted to investigate if the catalytic activity of CYLD was implicated in the perturbed TRK signalling seen in these cultures. However, reintroduction of wildtype-CYLD resulted in reduced cell viability, preventing further investigation in this model (Supplementary Figure 5 ). The dependence of perturbed TRK signalling seen on NFkB and JNK signalling was investigated by growing primary cultures in NFkB and JNK inhibitors; however, we were unable to conclusively show a clear effect on TRK levels (data not shown). Figure 4 TRK signalling is dysregulated in cylindroma and spiradenoma tissue. The expression levels of 24 526 genes from 32 microdissected tumours were pooled and compared against 10 pooled perilesional controls, and genes that were differentially expressed (P-value o0.01) were analysed by Ingenuity pathway analysis. Overexpressed transcripts are shown in red and underexpressed transcripts are shown in green. TRKB (NTRK2) and TRKC (NTRK3), members of the TRK signalling pathway, were overexpressed in tumour tissue compared with control samples. Expression of TRKA (NTRK1) however was reduced. Downstream members such as phosphatidylinositol-3-kinase and AKT and BCL2 were also over expressed. TRK, tropomyosin kinase.
Targeting TRK in CYLD defective tumours N Rajan et al To investigate whether dysregulated TRK signalling in patients with truncating CYLD mutations represented a druggable pathway, we used a 3D primary cell culture model. As seen in breast cancer (Lagadec et al., 2009) , TRK expression in vitro was low when 2D cylindroma cell culture was compared with tumours. 3D culture was associated with an increase in the expression of TRKB and TRKC, allowing us to use this as an in vitro model to assay cell viability in the presence of TRK inhibitors. The reduction in viability at micromolar concentrations of TRK inhibitors is encouraging, particularly as these tumours are amenable to transcutaneous or intra-lesional drug delivery. We attempted to determine whether the mechanism of action of TRK inhibition in our primary cell culture model was mediated by ERK or BCL2. This analysis proved not to be possible because of the high sensitivity of the primary cells to TRK inhibitors, resulting in only very few live cells after exposure to TRK inhibitors. The result seen with lestaurtinib is particularly interesting as this agent was recently found in a screen of 2800 compounds to be a potent inhibitor of NFkB, suggesting that it may target two key pathways in CYLD mutant tumours (Miller et al., 2010) . Lestaurtinib is currently in phase-3 clinical trials (Shabbir and Stuart, 2010) , and serum levels in patients on an 80-mg oral dose twice a day was 17-25 mm after taking the drug for 28 days (Marshall et al., 2005) , suggesting that the sensitivity of CYLD-defective tumours suggested by our model may Figure 5 TRKB and TRKC proteins are overexpressed in human cylindromas and spiradenomas. (a) TMAs of cylindromas and spiradenomas were probed with antibodies as indicated and visualised using a horseradish peroxidase-diaminobenzidene system, with haematoxylin used as a nuclear counterstain. Membranous TRKB and TRKC were overexpressed in the tumours, exemplified by the cylindroma tumours illustrated here. Patchy perinuclear TRKA staining was seen in some tumour cells. Expression of downstream targets phosphorylated ERK and BCL2 was also seen. The scale bars indicate 100 mm; the insets are shown to show specific membranous staining of TRKB and TRKC (2 Â enlargement of related image). (b, c) Membranous immunostaining scores of TRKC and TRKB were made on all cores on the array, with P-values of the difference in score (t-test) between tumour and control indicated in Table 3 . The error bars indicate the standard error of the mean. TMA, tissue microarray; TRK, tropomyosin kinase. 3.850 ± 0.1094 o0.0001 Cylindrospiradenoma (n ¼ 1)
4.600 ± 0.2449 o0.0001 Trichoepithelioma (n ¼ 1)
3.400 ± 0.4000 0.0038
Abbreviation: TRK, tropomyosin kinase. Membranous TRKC expression scores in cylindroma tumours compared with perilesional unaffected tissue. A custom tumour microarray was scored for membranous expression of TRKC. Mean scores were grouped by tumour type and compared with the scores of unaffected perilesional tissue.
Targeting TRK in CYLD defective tumours N Rajan et al be achievable in patients. As novel agents with increased pan-TRK specificity such as AZ-23 become available (Thress et al., 2009) , patients with truncating CYLD mutations may be another step closer to non-surgical alternatives for this disfiguring disease. We chose to investigate the expression of TRK in other human skin cancer models. The overexpression of membranous TRKC in a high proportion of BCCs is interesting. In sporadic BCC, LOH at 9p, the locus for PTCH1, has been found in the majority (93% in this series) of BCC (Teh et al., 2005) , whereas 16q, the locus for CYLD, appears rarely affected. TRKC signalling in non-melanoma skin cancer has not been characterised, but there are data from other models to support that TRK signalling could confer a proliferative advantage to cells where constitutively active SHH signalling following loss of functional PTCH could occur. Synergy between NT3, the cognate ligand for TRKC, and SHH has already been shown in murine motorneurons where both are important for growth, and use of NT3 antibodies in this system reduces the growth of these neurons (Dutton et al., 1999) . TRKC also directly interacts with bone morphogenetic signalling receptors (BMPRI) in murine epithelial cells and inhibits the tumour-suppressor effects of BMP signalling in a mouse colon cancer model. BMP and SHH signalling are tightly balanced, and BMP2, the ligand of BMPRI, has been shown to oppose SHH-mediated proliferation in murine cerebellar granular precursor cells through regulation of N-myc (Alvarez-Rodrı´guez et al., 2007) . Furthermore, BMP signalling is protective in cutaneous carcinoma, and a SMAD-4 conditional knockout expressed in murine keratinocytes has indeed shown to result in spontaneous SCCs and BCCs (Qiao et al., 2006) . It is hence conceivable that TRKCmediated inhibition of BMP signalling, on a mutated PTCH background in BCC, may have a pathogenic role. The localisation of TRKC at the invasive margin of BCC tumour islands suggests that this role may be in invasion (Supplementary Figure 2) . The mechanism that results in TRKC overexpression in BCC however remains to be explored. However, TRK receptors may represent a novel therapeutic target both in tumours with loss of CYLD function, but also for BCC, the most common cancer in humans.
Materials and methods
Tumour and blood samples Tumour tissue was obtained from patients undergoing surgery indicated to control tumour burden or for symptomatic relief, under regional ethical committee approval (REC REF:06/1001/ 59). Patients provided blood samples from which genomic DNA was extracted. Patients had been genotyped from all three pedigrees, and were confirmed to have the same mutation when entered into the study. These mutations were c.2460delc, c.2469 þ 1G4A and c.2290del5 (accession no. NM_015247).
Sample microdissection
All samples for microarray studies were snap frozen immediately after surgery, with detailed location maps of the tumours made at the time. Tumour blocks were mounted in an optimal cutting temperature compound and sectioned on a cryostat at 12 mm onto RNAse-free Superfrost coated slides (VWR). All subsequent steps were performed in RNAse-free solutions. Tissue sections were fixed in 100% ethanol at À20 1C for 2 min and then washed in 70% DEPC-treated ethanol, and treated with 50% DEPC-treated ethanol for a further 2 min. The sections were stained with a crystal violet solution (Ambion, Austin, TX, USA) for 40 s and then dehydrated in increasing concentrations of ethanol. Slides were then stored on dry ice until needle microdissection was performed. Microdissection was performed at 4 1C using a Leica dissecting microscope. The dissected samples were placed directly into Trizol (Invitrogen, Paisley, UK). Needle homogenisation was performed and the sample was frozen at À80 1C until RNA and DNA extraction was performed.
RNA and DNA extraction from tissue Trizol was used to extract RNA and DNA from the samples. The standard supplied protocol was used, with glycogen added to aid precipitation of RNA into the aqueous phase. RNA was quantified using a Nanodrop spectrophotometer (Nanodrop, Wilmington, DE, USA). RNA integrity analysis was performed using a chip-based electrophoresis kit to confirm preservation of the 18S and 28S ribosomal bands (RNA 6000 Nano and Pico Chip kits; Agilent 2100 Bioanalyzer).
DNA extraction from peripheral blood
Genomic DNA was extracted from peripheral blood using the Qiagen whole-blood kit (Qiagen, Crawley, UK) according to the manufacturer's protocols.
Array CGH
The 32K BAC re-array collection (CHORI) tiling path array comparative genomic hybridisation platform was constructed at the Breakthrough Breast Cancer Research Centre, as described earlier by Marchio et al. (2008) . This type of BAC array platform has been shown to be as robust as and to have comparable resolution with high-density oligonucleotide arrays. DNA labelling, array hybridisations and image acquisition were performed as described earlier by Turner et al. (2010) . Array comparative genomic hybridisation data were pre-processed and analysed using an in-house R script (BACE.R) in R version 2.9.0 as previously described by Natrajan et al. (2009) . After filtering polymorphic BACs, a final data set of 31 544 clones with unambiguous mapping information according to the August 2009 build (hg19) of the human genome (http://www.ensembl.org) was smoothed using the circular binary segmentation (cbs) algorithm (Natrajan et al., 2009) . A categorical analysis was applied to the BACs after classifying them as representing amplification (40.45), gain (40.12 and o0.44), loss (oÀ0.12) or no-change according to their cbs-smoothed log 2 ratio values. ArrayCGH data were deposited at ROCK (http://brcabase.icr.ac. uk/index.jsp), at the following URL: http://rock.icr.ac.uk/ collaborations/Rajan/Cylindroma.
SNP typing
Genomic DNA was extracted from microdissected tissue and assayed on an Illumina 550K SNP array according to the manufacturer's protocols. SNP array data were deposited at ROCK (http://brcabase.icr.ac.uk/index.jsp), at the following URL: http://rock.icr.ac.uk/collaborations/Rajan/Cylindroma.
Restriction enzyme allelotyping
PCR was performed using primers (5 0 -3 0 ) CYLD18F GAG AGCTTAAGCAGATGGAA and CYLD18R TAAACAGA AAAGGCAAAAGC that flanked exon-18, and the PCR product was subject to restriction enzyme digestion using HpyCH4V (c.2460delc) and SmlI (c.2469 þ 1G4A). The digested products were separated on agarose gel and visualised using ethidium bromide using a UV transilluminator. LOH was determined by the absence of a band that corresponded with loss of the wild-type allele in both cases.
Gene expression profiling
The Illumina WG-DASL platform was used for each sample that allowed monitoring of the gene expression of 24 526 transcripts. A 50-ng weight of total RNA from each sample was converted to cDNA as per the supplied protocol and then hybridised to Illumina Human 8 v3 chips. A confocal Illumina Infinuim bead reader then scanned the chips and the results were extracted using the Illumina Beadstudio software. The microarray gene expression profiles were deposited at Arrayexpress (www.ebi.ac.uk) under accession number E-MTAB-352. (e, f) Cylindroma cells were subject to lentivirus-mediated short-hairpin RNA knockdown of TRKB and TRKC, and these were compared against a control hairpin. Knockdown was assessed at the protein level by immunoblotting. (g, h) Transcript expression of TRKB and TRKC is reduced following lentiviral knockdown. (i) Following puromycin selection, GFP-positive cells were plated and grown over 12 days. TRKB and TRKC knockdown resulted in reduced colony formation. (j) Similar results were seen in a short-term cell viability assay. All experiments were repeated at least three times. The error bars indicate the standard error of the mean and the scale bars represent a distance of 100 mm. DAPI, 4 0 ,6-diamidino-2-phenylindole; GFP, green fluorescent protein; TRK, tropomyosin kinase. (a) Cylindroma primary cell cultures were plated onto collagen-coated tissue culture scaffolds (3D cell culture) and grown for 28 days in the same conditions as standard 2D cell culture. Tissue culture scaffolds were fixed and stained with haematoxylin and eosin ( Â 20 original magnification expression; scale bar 100 mm) (b, c) Total cell lysates from fresh tumours, 3D and 2D cell cultures were separated using sodium dodecyl sulphate-PAGE, and immunoblots were probed using (b) TRKB and (c) TRKC antibodies. Lanes 1 and 2 were loaded with 5 mg of cell lysate from fresh tumours, labelled 'Cylindroma 1 and 2', rest 20 mg of lysate from primary cell cultures in 3D (PCC 2,4 3D) and cultures in 2D (PCC 2,4 2D). TRKB and TRKC were expressed at higher levels in 3D cell cultures (lanes 3 and 5) compared with matched 2D cultures (lanes 4 and 6). (d, e) Cylindroma cells were grown on 3D scaffolds and stimulated with NGF, BDNF and NT3 for the periods indicated, and then transferred to ice-cold phosphate-buffered saline, and cell lysates were extracted for immunoblotting. Membranes were probed with antibodies against phosphorylated ERK and BCL2. Increased levels of phosphorylated ERK and BCL2 were seen. All experiments were repeated at least three times. 2D, two-dimensional; 3D, three-dimensional; BDNF, brain-derived neurotrophic factor; NGF, nerve growth factor; PCC, primary cell culture; TRK, tropomyosin kinase.
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Data normalisation and analysis
Raw gene expression values were normalised using quantile normalisation. Differential expression analysis was performed using the Beadstudio software to detect significantly different expressed genes. Differences in signal values for each gene were scored with a differential score. Bonferroni testing was performed to correct for multiple hypothesis testing, and the results were ranked in order of differential score, with a differential score ranging from þ 374 to À374, with ±65 corresponding to a P-value cut off of o0.01. Signal values from genes that fulfilled this level of significance were analysed for fold change and results have been tabulated in Table 1 . Pathway discovery was further aided by the Ingenuity pathway analysis software. Finally, a parallel analysis was performed by gene set expression analysis. For this analysis, probe values (24 526) were collapsed to gene symbols (18 630), with the maximum probe value used for replicate probes. After filtering, 867 gene sets were used in the analysis. The gene sets were permutated 1000 times, before being ranked in order using a 'difference of classes' metric, with a weighted enrichment statistic applied. Fifty-six gene sets were significantly enriched at a nominal P-value of o0.01.
Quantitative PCR
Total RNA was extracted from cylindroma primary cell cultures as described above, subject to DNAse digestion and then reverse-transcribed using the Superscript III kit (Invitrogen) according to the manufacturer's instructions. cDNA was then used for quantitative PCR using the following primers (5 0 -3 0 ): GAPDH F, ATGGGGAAGGTGAAGGTCG; GAPDH R, GGGGTCATTGATGGCAACAATA; NTRK2 F, TGTT CAGCACATCAAGCGACA; NTRK2 R, GCTCAGGACAG AGGTTATAGCAT; NTRK3 F, TCCGTCAGGGACACAA CTG; NTRK3 R, GCACACTCCATAGAACTTGACA, using an SYBR green-containing Taq polymerase master mix (Sigma, Dorset, UK), in an ABI 7900HT thermal cycler. Gene expression was normalised to GAPDH and comparisons in expression were made using the 2 ÀDDCT formula as the PCR reactions had similar efficiencies of amplification.
Immunoblotting
Homogenised tumour samples and lysates were sonicated in lysis buffer (65 mM Tris, 50 mM NaCl, 5 mM EDTA, 1 mM phenylmethyl-sulphonyl fluoride, 1 mM sodium orthovanadate, 0.1% sodium dodecyl sulphate, 2% Triton X and 1% NP-40) with added phosphatase and protease inhibitors (Roche, Hertfordshire, UK). A 5-to 20-mg weight of total protein was loaded onto sodium dodecyl sulphate-PAGE gels and then transferred to polyvinylidene difluoride membranes. Immuno- Figure 8 Cylindroma 3D primary cell cultures show increased sensitivity to TRK inhibitors relative to aspirin. (a-d) Cylindroma 3D cell cultures were grown for 2 weeks in the presence of salicylic acid, K252a, tyrphostin AG879 and lestaurtinib (CEP-701) in triplicate in a 96-well format. This was repeated using at least three different tumours from different body sites of three patients. Cell viability was assessed using a luminescent cell viability assay at the end of this period and dose response curves were generated. Cylindroma cells were sensitive to lestaurtinib at micromolar levels, whereas salicylic acid had a similar effect at millimolar levels. 3D, three-dimensional; TRK, tropomyosin kinase. Healthcare, Bucks, UK) . The immunoblots were exposed to a Biomax XR film and processed routinely.
Tissue microarray
A custom-made TMA was made from single 2-mm cores from representative tumour areas and was used to validate protein expression in tissue sections. The TMA contained 10 cylindroma samples, four spiradenoma samples and two trichoepithelioma samples. The cylindromas and spiradeno- Targeting TRK in CYLD defective tumours N Rajan et al mas were chosen from both scalp and torso, and trichoepitheliomas were from face. Human skin cancer TMA slides (A216) were purchased from Stretton Scientfic (Stretton, UK).
Immunohistochemistry on paraffin-embedded sections and TMAs
Tissue sections from the TMA were de-waxed with xylene and rehydrated in graded ethanols before undergoing microwave antigen retrieval in sodium citrate buffer (pH 6.0). The tissue sections were then blocked with a peroxidase-blocking agent (Dako, Cambridgeshire, UK) and then incubated with the following primary antibodies: TRKA, TRKB, TRKC, p44/42 (phosphorylated ERK) and BCL2. The tissue sections were then washed in phosphate-buffered saline and probed with secondary horseradish peroxidase-conjugated antibodies, and staining was visualised with 3,3 0 -diaminobenzidine. Haematoxylin was used as a nuclear counterstain. The perilesional epidermis was used as negative control, and anagen hair follicles in perilesional tissue served as positive control for TRK antibodies.
Immunohistochemistry scoring of TRK expression
Tissue sections were assessed for staining in five randomly selected high-power fields per core on the TMA. A modified version of an established score to assess membranous staining of Her-2 was developed (Kavanagh et al., 2009) .To quantify TRK staining, tumour cells were scored as having circumferential strong membranous staining (3), strong non-circumferential staining (2), weak staining (1) or no staining (0). The proportion of such cells stained was counted per high-power field under a Â 63 objective using a Leica DMR microscope and scored as follows: 75-100% of cells (3), 50-75% (2) and less than 50% (1). A total score of up to 6 was possible per field per core and scores were compared with perilesional keratinocytes for statistical significance using t-test.
Cylindroma primary cell culture and drug inhibition experiments
Cylindroma samples were micro-dissected using a Zeiss microscope after surgery and tumour pieces were enzymatically digested in 2.5% trypsin. A cell suspension was then counted for viable cells using Trypan blue and the cells were plated in collagen-coated tissue culture plasticware and grown in keratinocyte serum-free medium. Lentiviral transfection was performed using short-hairpin RNA against TRKB and TRKC, and compared with a non-silencing control (Openbiosystems, Thermo Scientific, Surrey, UK). Cells were grown in puromycin selection media till all cells were GFP-positive and then used for experiments. For colony-forming assays, cells were plated at a low density of 4000 cells per well of a sixwell plate. These cells were maintained for 10-14 days, before they were fixed in 3.3% trichloroacetic acid, and stained with 0.57% sulphorhodamine in 1% acetic acid. The plates were then scanned and colonies with more than 10 cells were counted. For short-term viability assays, cells were grown in a 96-well format for 96 h before cell viability was assayed using a luminescent assay that lysed cells and used liberated ATP as readout for viability (CellTiter Glo; Promega, Southampton, UK). This was performed according to standard manufacturer's protocols and luminescence was read using a luminometer (Luminoskan-Ascent, Thermo Scientific). For 3D cultures, cells were seeded on a polystyrene collagen-coated scaffold (Reinnervate, Co., Durham, UK), grown for 28 days and then treated with drugs. Cells grown in the following inhibitors were used, diluted in dimethylsulphoxide, with a final concentration of dimethylsulphoxide at 0.1%: K252a and tyrphostin AG879, salicylic acid (Sigma), lestaurtinib (Toronto Research Chemicals, Ontario, Canada). After 14 days CellTiter Glo (Promega) was added to the media according to standard manufacturer's protocols and luminescence was read using a luminometer (Luminoskan-Ascent). All experiments were performed in triplicate.
Fluorescence-activated cell sorting analysis Cells were trypsinised, resuspended in phosphate-buffered saline and fixed by adding ice-cold ethanol while gently vortexing the tube, until a final concentration of 70% ethanol was reached. The cells were fixed for 1 h at 4 1C. Cells were then pelleted and resuspended in Cystain Solution (Partech, Kent, UK), which stained the nuclear DNA with 4 0 ,6diamidino-2-phenylindole (DAPI). Cells were stained for 1 h in the dark at 4 1C before analysis on a FACSCanto II flow cytometer (Becton Dickinson, Oxford, UK) using a UV laser. The cells were analysed for total DNA content and a minimum of 10 000 events were used for cell-cycle data. All cell-cycle data were analysed using Modfit (Verity Software House, Topsham, ME, USA).
